NCCN Session Offers Considerations for Frontline, Second-Line Treatment Choices in CLL
AJMC,
The ALPINE trial, which examined frontline use of the second-generation Bruton tyrosine kinase (BTK) inhibitor zanubrutinib (Bruk…
The ALPINE trial, which examined frontline use of the second-generation Bruton tyrosine kinase (BTK) inhibitor zanubrutinib (Bruk…
Patients now have multiple options, including continuous therapy with BTK inhibitors and fixed-duration therapy with venetoclax-b…
Updated efficacy outcomes of the phase 3 MURANO trial demonstrated that fixed-duration venetoclax plus rituximab is an…
Targeted therapies have helped to improve responses in patients with relapsed chronic lymphocytic leukemia (CLL) regardless of…